Ignite Creation Date:
2025-12-24 @ 12:02 PM
Ignite Modification Date:
2026-02-26 @ 6:52 AM
Study NCT ID:
NCT00457561
Status:
COMPLETED
Last Update Posted:
2007-04-06
First Post:
2007-04-05
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'DEFINED_POPULATION'}}, 'statusModule': {'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2007-04', 'lastUpdateSubmitDate': '2007-04-05', 'studyFirstSubmitDate': '2007-04-05', 'studyFirstSubmitQcDate': '2007-04-05', 'lastUpdatePostDateStruct': {'date': '2007-04-06', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2007-04-06', 'type': 'ESTIMATED'}}, 'conditionsModule': {'keywords': ['The relationship between all-cause mortality in patients introduced hemodialysis and recombinant human erythropoietin dose and serum adiponectin level'], 'conditions': ['Hemodialysis']}, 'descriptionModule': {'briefSummary': 'Decreased body fat mass, possibly mediated through the effects of elevated serum adiponectin levels, may be associated with requirements for higher recombinant human erythropoietin doses and a subsequent worse prognosis in patients beginning hemodialysis.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients who started hemodialysis therapy from August 2000 to May 2001 in 11 dialysis centers in the Shizuoka prefecture area, and who survived for more than 3 months after the start of hemodialysis.\n\nExclusion Criteria:\n\n* Nothing particular.'}, 'identificationModule': {'nctId': 'NCT00457561', 'briefTitle': 'Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis', 'organization': {'class': 'OTHER', 'fullName': 'Hamamatsu University'}, 'orgStudyIdInfo': {'id': '19710808'}}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Naro Ohashi, MD,PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'First Department of Medicine, Hamamatsu University School of Medicine'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hamamatsu University', 'class': 'OTHER'}}}}